Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo-controlled trial.
Ida Kirstine Bull RasmussenEmilie H ZobelRasmus S RipaBernt J von ScholtenViktor Rotbain CurovicJacob K JensenAndreas KjaerTine Willum HansenPeter RossingPublished in: Diabetes, obesity & metabolism (2021)
Treatment with liraglutide for 26 weeks was associated with a reduction in cardiac adipose tissue compared to placebo. The reduction was not independent of weight loss, suggesting that this is not a drug-specific effect.
Keyphrases
- adipose tissue
- double blind
- type diabetes
- insulin resistance
- weight loss
- placebo controlled
- left ventricular
- phase iii
- high fat diet
- clinical trial
- open label
- bariatric surgery
- glycemic control
- cardiovascular disease
- phase ii
- heart failure
- randomized controlled trial
- drug induced
- combination therapy
- metabolic syndrome
- gastric bypass
- atrial fibrillation
- body mass index
- replacement therapy
- adverse drug